Nahid Kennedy, DO
Internal Medicine · Hanover, MANPI 1871561597
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$898
- Boehringer Ingelheim$356
- GSK$281
- Amgen$278
- Novartis$222
- Neurocrine Biosciences, Inc.$199
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,143100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 46 | $898 |
| Boehringer Ingelheim | 14 | $356 |
| GSK | 11 | $281 |
| Amgen(2 entities) | 9 | $278 |
| Novartis | 13 | $222 |
| Neurocrine Biosciences, Inc. | 11 | $199 |
| Lilly USA, LLC | 9 | $182 |
| Johnson & Johnson | 8 | $180 |
| Novo Nordisk | 10 | $175 |
| Teva Pharmaceuticals USA, Inc. | 9 | $164 |
| Exact Sciences | 6 | $152 |
| E.r. Squibb & Sons, L.L.C. | 5 | $138 |
| Avanir Pharmaceuticals, Inc. | 7 | $135 |
| AbbVie | 4 | $93 |
| Sunovion Pharmaceuticals Inc. | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Eisai Inc. | 3 | $62 |
| Seqirus USA Inc | 3 | $60 |
| AstraZeneca | 3 | $58 |
| Bausch Health US, LLC | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Hologic Sales And Service, LLC | 3 | $37 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Biogen | 2 | $28 |
| UCB, Inc. | 1 | $26 |
| Mylan Pharmaceuticals Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $23 |
| Cequr Corporation | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| BD | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Edwards Lifesciences | 1 | $14 |
| Qiagen, LLC | 1 | $12 |
How this compares
$4,143 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $91,110 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $16,837 |
| OzempicSemaglutide | 12 | $15,663 |
| XareltoRivaroxaban | 24 | $10,173 |
| JanuviaSitagliptin Phosphate | 19 | $9,291 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,130 |
| JardianceEmpagliflozin | 19 | $6,880 |
| NeuproRotigotine | 24 | $6,833 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,418 |
| Atorvastatin Calcium | 455 | $5,274 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,106 |
| Memantine Hcl | 110 | $4,159 |
| Mirtazapine | 165 | $3,909 |
| Metoprolol Succinate | 273 | $3,882 |
| Divalproex Sodium | 130 | $3,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $898 | $91,110239 claims |
| GSKIncruse Ellipta, Trelegy Ellipta, Breo Ellipta | $281 | $29,07359 claims |
| Novo NordiskOzempic | $175 | $15,66312 claims |
| Johnson & JohnsonXarelto | $180 | $10,17324 claims |
| Boehringer IngelheimJardiance | $356 | $6,88019 claims |
| UCB, Inc.Neupro | $26 | $6,83324 claims |
| AstraZenecaSymbicort | $58 | $2,77812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Hanover
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.